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made on a drug-by-drug basis. Free, unbound concentrations should 
always be measured rather than estimated, and used as the primary 
input for PK/PD correlations, as well as for statements on the safety 
and efficacy of drugs [1]. 
Warfarin (Coumadin) is a widely used anticoagulant. 
Warfarin is indicated for treatment of venous thromboembolism, 
atrial fibrillation, mechanical and bioprosthetic heart valves, post-
myocardial infarction, and recurrent systemic embolism. Warfarin 
consists of a racemic mixture of two active enantiomers: R- and S- 
forms [2,3]. Warfarin is a narrow therapeutic range drug and can 
cause major or fatal bleeding. Approximately 99% of the drug is 
bound to human plasma albumins [3]. One of the pharmacokinetic 
mechanisms for drug interactions with warfarin is protein binding 
interaction. This interaction can result in displacement of warfarin 
from the protein binding site, increase warfarin free plasma 
concentration, and increase the risk of warfarin toxicity. Free drug 
plasma concentrations must be carefully monitored during warfarin 
therapy.
Nitazoxanide (Alinia) is an anti-infective prodrug, which 
converts to an active metabolite tizoxanide very fast. The parent 
nitazoxanide is not detected in plasma. Tizoxanide is active against 
anaerobic bacteria, protozoan parasites, and viruses [4,5]. Tizoxanide 
is highly bound to plasma proteins (>99 %) [4,6].Caution should 
be used when administering nitazoxanide concurrently with other 
highly plasma protein-bound drugs, especially drugs with narrow 
therapeutic indices, as competition for binding sites may occur.
Tizoxanide is compound that is expected to be co-administered 
with warfarin clinically and have the potential to alter warfarin 
protein binding. No drug-drug protein binding interaction studies 
have been reported for warfarin and tizoxanide.
The overall goal of the research was to evaluate the potential for 
inhibition of protein binding of warfarin by tizoxanide, which can be 
expected to be co-administered with warfarin in the patients.
Introduction
Many drugs are bound to proteins within the body. There is 
marked variability in the extent to which the drugs bind to the 
proteins. The degree of drug-protein binding might affect a drug’s 
efficiency. Drugs can be bound to plasma proteins as well as tissue 
proteins. Plasma protein binding can have multiple effects on the 
pharmacokinetics (PK) of a drug. The binding of drug to plasma 
proteins is a major determinant of drug disposition. When a drug 
is bound to the plasma proteins, it is not actively distributed to the 
site of action to interact with the target tissues. Moreover, the bound 
drug is kept in the blood, while the unbound (free) fraction may be 
metabolized or excreted. The binding has a very important effect also 
on drug pharmacodynamics (PD). Only the free drug interacts with 
receptors, therefore only the free drug can produce therapeutic effect. 
Common blood proteins that bind drugs are human serum albumins, 
lipoproteins, glycoproteins, and globulins. Albumin is the most 
abundant protein in the blood plasma. Many medications extensively 
bind to the albumins.
Protein binding interactions are displacement reactions, which 
have been implicated as the causative mechanisms in many drug-drug 
interactions. Competitive displacement interactions are predominant 
ones among protein binding reactions. The competitive protein 
binding drug-drug interactions result in increased the free plasma 
concentrations of the displaced medications. Clinically displacement 
reactions acquire importance when the displaced drug is highly 
bound to plasma proteins. In this case the displacer drug produces a 
very rapid and significant increase in the plasma concentrations of the 
displaced medication. The result of this interaction can be dramatic 
if the second drug is a drug with narrow therapeutic index. Such type 
of interactions can lead to enhanced pharmacological effects and, 
possibly, toxicity of the displaced medication.
A simple, generalized guideline for the evaluation of the clinical 
significance of protein binding interactions frequently cannot be 
applied. Instead, a careful analysis of protein binding effects must be 
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Materials and Methods
Materials
Warfarin, DMSO, acetonitrile and all other chemicals were 
obtained from Sigma-Aldrich (St. Louis, MO). Tizoxanide was 
purchased from Cayman Chemical (Tallinn, Estonia). HPLC nylon 
filter (0.45 micron, 47 mm) was purchased from Pall Life Science 
(Port Washington, NY). Human plasma was purchased from Valley 
Biomedical (Winchester, VA). Amicon Centrifree YM-30 (molecular 
weight cut off 30K) centrifugal filter devices were obtained from 
Millipore Corporation (Billerica, MA, USA).
Study groups
The studies were divided into two phases. Four experiments were 
performed for each study group. Phase I studies generated baseline 
protein binding values for warfarin. The compound was dosed alone. 
Phase II studies was conducted to assess the effect of tizoxanide 
on warfarin protein binding. Warfarin and tizoxanide were dosed 
together. Tizoxanide was selected based on its potential to be co-
administered with warfarin in the clinical setting as well as its protein 
binding profile. Warfarin protein binding data of Phase I studies were 
compared to the warfarin binding values of Phase II studies. Warfarin 
concentrations were determined by HPLC.
Analytical method for warfarin
Warfarin was measured in all samples by validated HPLC 
method. Separation was accomplished using a C18 column (100 mm 
X 4.6 mm, 2.6µ, and 100Ao) with a pre-column filter. The C18 column 
was temperature controlled at 30oC. Measurements were performed 
with ultraviolet detection at a wavelength of 220 nm. Mobile phase 
consisted of 35% acetonitrile and 65% 10 mM phosphate buffer 
(KH2PO4, pH 6.5). Analysis was conducted at ambient temperature 
at a constant flow rate of 1.0 mL/min using isocratic elution. Six 
microliters of the resultant ultrafiltrate was injected into the HPLC.
Binding assessments
Nonspecific binding to ultra filtration device: A preliminary 
study was performed to identify warfarin nonspecific binding to the 
ultrafiltration device. Aqueous solution of warfarin was added to an 
ultrafiltration device (Amicon Centrifree Micropartition System). 
The system was centrifuged for 15 minutes. The ultrafiltrate was 
assayed to determine warfarin binding to the ultrafiltration system. 
Samples were analyzed by HPLC. The studies were performed in 
triplicate.
Protein binding determination: Plasma protein binding of 
warfarin was evaluated using ultrafiltration. Studies were carried 
out at physiologic temperature and pH. Aliquots of human plasma 
were placed in test tubes and spiked with stock solutions of warfarin 
to generate samples of varying concentrations (e.g., 50, 75, and 100 
µg/ml). Tizoxanide (500 µg/mL) was added only for interaction 
studies (Phase II). Samples were allowed to equilibrate in shaker bath 
(37OC) for 30 minutes. An aliquot (1 ml) of warfarin human plasma 
was added to an Amicon Centrifree Micropartition System (MW 
cutoff 30,0000). The system was centrifuged for 15 minutes @ 1500 
g. The ultrafiltrate was assayed for determination of free warfarin 
concentrations. Samples were analyzed by HPLC. All experiments 
were performed in quadruplicate.
Data analysis
Unbound fraction (fu) of warfarin was calculated as a ratio of 







Where: fu is unbound (free) fraction
 Cu is unbound (free) concentration of warfarin
 Ct is total concentration of warfarin
Statistical analysis
Mean estimates of protein binding parameters were compared 
using ANOVA. In this manner, differences in protein binding of 
warfarin were detected between study groups. Statistical significance 
was taken as a p-value <0.05.
Results
Protein binding of warfarin was investigated using a centrifugal 
ultrafiltration technique. Experiments were conducted over a range 
of warfarin concentrations from 50 to 100µg/mL. Preliminary studies 
(i.e., fraction unbound ~ 1) found negligible binding of warfarin to 
the ultrafiltration device (Amicon Centrifree™ YM-30 micropartition 
devices). Warfarin protein binding data presented in Table 1.
Phase I studies generated baseline protein binding values for 
warfarin. Mean fraction unbound (fu) of warfarin was 0.012 in Phase I 
studies. No significant differences were found between concentrations 
studied.
Phase II studies were conducted to evaluate protein binding 
of warfarin in the presence of tizoxanide. Mean fraction unbound 
of warfarin in Phase II studies was 0.31. Tizoxanide increased free 
fraction (fu) of warfarin 34, 28, and 20-fold for concentration of 50, 75, 
and 100 ug/ml, respectively. The results revealed that protein binding 
values were not significantly different within both study groups.
Discussion
This research was conducted to characterize the effect of 
tizoxanide on protein binding of warfarin. Warfarin was of particular 
interest for the present investigation because it has been shown to be 
highly bound to plasma proteins and is a narrow therapeutic index 
drug. Tizoxanide, an active metabolite of an anti-infective prodrug 
nitazoxanide, is highly bound to plasma proteins and expected to 
be co-administered with warfarin clinically. There is a possibility 
for protein binding drug-drug interaction between warfarin and 
tizoxanide.
Study Groups Warfarin Concentrations (µg/mL)













Table 1: Protein Binding of Warfarin.
*Data reported as mean (SD)
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The study evaluated the potential for statistically significant drug–
drug interaction between warfarin and tizoxanide. Co-administration 
of tizoxanide significantly inhibited protein binding of warfarin for 
all concentrations tested. Tizoxanide amplified free concentrations of 
warfarin by displacing warfarin from the protein binding site.
The studies on supermolecular interaction of warfarin with 
human albumins revealed that warfarin predominantly bound to 
albumins [7]. Protein binding of tizoxanide is not well investigated. 
Some studies were conducted in goat plasma and in the solutions of 
albumin and alpha-1-acid-glycoprotein. The investigation showed 
that tizoxanide in plasma and in the albumin solution achieved a 
protein binding percentage of more than 95%, while in the solution 
of alpha-1-acid-glycoprotein; the percentage was only about 49%. The 
result suggested that tizoxanide has much more potent binding ability 
with albumin than with alpha-1-acid-glycoprotein, resulting from its 
acidic property [6].
The both compounds warfarin and tizoxanide bind predominantly 
to albumins and, most probably, competed for the same binding 
site of the protein. Albumins have two main drug binding sites 
characterized as Sudlow site I and Sudlow site II [8]. These sites bind 
drugs selectively. Warfarin primarily binds to the site I [9,10]. Because 
tizoxanide displaced warfarin from its binding site we can suggest 
that tizoxanide also has high affinity to the albumin binding site I and 
the both drugs have competed for the shared binding Sudlow site I of 
albumins. This assumption requires further investigation.
Displacement of one drug by another from blood proteins can 
modify the pharmacokinetics of the displaced drug. For some drugs, 
displacement from blood proteins causes only mild changes in free 
plasma drug concentrations and the altered plasma binding would 
not be expected to influence the pharmacological response. In this 
case dose adjustments are not required.
However, plasma binding displacement interactions become 
clinically important when the displaced medication is a narrow 
therapeutic index drug. There has been concern that inhibition of 
warfarin protein binding could affect the anticoagulant activity of 
the drug. By decreasing protein binding of warfarin, tizoxanide 
increased the plasma concentrations of free warfarin, although total 
drug concentrations in blood were unchanged. This could result 
in enhanced pharmacological response and increased toxicity of 
warfarin. It is very dangerous for the patient stabilized on warfarin. 
Such interaction can increase the risk of bleeding and may require a 
dose adjustment (reduction) of warfarin.
Furthermore, tizoxanide may displace other highly albumin-
bound drugs from their binding sites. Caution should be used 
when administering nitazoxanide concurrently with highly plasma 
protein-bound drugs, especially drugs with narrow therapeutic 
indices, as competition for binding sites may occur. Future studies 
are required to monitor and evaluate the effects of these potential 
drug-drug interactions. The studies will include in vitro experiments 
to assess valuable kinetic parameters of the interaction followed by 
experiments to evaluate the magnitude of the interaction in vivo.
Conclusion
The studies provided meaningful insights regarding the 
inhibition of warfarin protein binding. Protein-binding displacement 
interactions were observed in the in vitro experiments with warfarin 
and tizoxanide. It was concluded that tizoxanide has the potential 
to alter protein binding of warfarin and produce variations in 
unbound warfarin plasma concentrations. Even slight variations 
in warfarin plasma exposure may result in large variations in the 
pharmacological response. The interaction could potentially result 
in increasing the toxicity of warfarin therapy and increase the risk 
of bleeding. However, further studies are needed to evaluate clinical 
significance of the finding. If the magnitude of the clinical interaction 
is significant, dose adjustments of warfarin may be necessary when 
co-administered with nitazoxanide.
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